Pfizer Inc. (NYSE:PFE) Stake Decreased by Truvestments Capital LLC

Truvestments Capital LLC lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 4.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 33,264 shares of the biopharmaceutical company’s stock after selling 1,436 shares during the period. Truvestments Capital LLC’s holdings in Pfizer were worth $1,195,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in PFE. Signet Financial Management LLC lifted its position in shares of Pfizer by 0.4% during the 4th quarter. Signet Financial Management LLC now owns 71,686 shares of the biopharmaceutical company’s stock valued at $3,129,000 after acquiring an additional 292 shares during the period. Semmax Financial Advisors Inc. acquired a new stake in shares of Pfizer in the fourth quarter worth about $585,000. Nomura Holdings Inc. lifted its position in shares of Pfizer by 1,854.2% in the fourth quarter. Nomura Holdings Inc. now owns 529,323 shares of the biopharmaceutical company’s stock worth $22,956,000 after buying an additional 502,237 shares during the last quarter. LMR Partners LLP acquired a new stake in shares of Pfizer in the fourth quarter worth about $2,920,000. Finally, IHT Wealth Management LLC lifted its position in shares of Pfizer by 42.3% in the fourth quarter. IHT Wealth Management LLC now owns 48,934 shares of the biopharmaceutical company’s stock worth $2,136,000 after buying an additional 14,554 shares during the last quarter. 71.69% of the stock is currently owned by institutional investors.

NYSE:PFE traded up $0.57 during midday trading on Friday, reaching $36.36. 284,702 shares of the company traded hands, compared to its average volume of 19,407,336. Pfizer Inc. has a twelve month low of $33.97 and a twelve month high of $46.47. The firm has a market capitalization of $195.97 billion, a price-to-earnings ratio of 12.13, a price-to-earnings-growth ratio of 2.82 and a beta of 0.66. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.47 and a quick ratio of 1.21. The company has a fifty day moving average price of $35.94 and a 200 day moving average price of $39.97.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.05. Pfizer had a return on equity of 28.10% and a net margin of 23.58%. The business had revenue of $13.26 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the previous year, the firm posted $0.77 EPS. The business’s revenue for the quarter was down 1.5% compared to the same quarter last year. On average, equities research analysts forecast that Pfizer Inc. will post 2.81 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a dividend of $0.36 per share. This represents a $1.44 annualized dividend and a yield of 3.96%. The ex-dividend date is Thursday, November 7th. Pfizer’s payout ratio is currently 48.00%.

Several research firms recently weighed in on PFE. Bank of America cut Pfizer from a “buy” rating to a “neutral” rating in a research report on Tuesday, July 30th. JPMorgan Chase & Co. lifted their target price on Pfizer from $37.00 to $46.00 and gave the stock a “neutral” rating in a research report on Thursday, September 19th. They noted that the move was a valuation call. Zacks Investment Research upgraded Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 target price for the company in a research report on Tuesday, October 1st. Credit Suisse Group reiterated a “neutral” rating on shares of Pfizer in a research report on Monday, August 12th. Finally, Morgan Stanley decreased their target price on Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a research report on Tuesday, August 27th. Twelve investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Pfizer has an average rating of “Hold” and an average price target of $45.20.

In other Pfizer news, Director Scott Gottlieb bought 3,000 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were purchased at an average price of $34.72 per share, with a total value of $104,160.00. Following the purchase, the director now directly owns 3,000 shares of the company’s stock, valued at $104,160. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Pfizer Inc bought 50,000 shares of the business’s stock in a transaction on Tuesday, September 17th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $900,000.00. The disclosure for this purchase can be found here. 0.09% of the stock is owned by insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: Stock Symbols, CUSIP and Other Stock Identifiers

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.